Skin Cancer (Nonmelanoma)

Are your patients sunscreen savvy?
September 18, 2020

A recent survey shows that many consumers are confused about sunscreen labeling claims regarding sun protection factor (SPF), allergenicity and other features.

Monitor cutaneous squamous cell carcinoma patients closely after initial diagnosis
September 18, 2020

Cutaneous squamous cell carcinoma (cSCC) patients need close clinical follow-up after being diagnosed with the skin cancer because subsequent cSCC development is likely in the following months and years.

When is the best time to follow-up after Mohs surgery?
September 11, 2020

A recent study from the University of Missouri School of Medicine investigates when is the best time to make post-operative phone calls to patients following Mohs micrographic surgeries.

Castle Biosciences launches test to predict metastasis risk in cSCC
September 09, 2020

Castle Biosciences announces the launch of DecisionDx-SCC, a prognostic gene expression profile test for patients with high-risk cutaneous squamous cell carcinoma (cSCC).

Collaboration makes progresses standards for implementing AI
August 11, 2020

The International Skin Imaging Collaboration is an academic and industry partnership designed to facilitate the clinical application of digital skin imaging, with an initial focus on melanoma. The group is developing standards for dermatologic imaging and building a public archive of clinical and dermoscopic images for use in developing artificial intelligence diagnostic algorithms.

Survey findings inform messaging on UV exposure
July 31, 2020

Findings from a survey of college students examining beliefs about UV exposure and sunscreen use and their associations with skin cancer risk and UV protective behaviors provide some insights for patient counseling.

Studies examine ingredient safety over lifetime use
July 30, 2020

Findings of initial studies and call for further testing should not be misconstrued to mean ingredients are unsafe.

Immune checkpoint inhibitor therapy advances treatment for Merkel cell carcinoma
July 14, 2020

Treatment for Merkel cell carcinoma has evolved due to the high aggressiveness and metastatic rate of the tumors. Immune checkpoint inhibitor therapy may change prognosis and quality of life.

Immunotherapy implications for NMSC
July 13, 2020

The biology of nonmelanoma skin cancers and their strong immunogenicity makes these tumors good candidates for novel and emerging immunotherapeutic agents.

Pembrolizumab approved by FDA for cSCC
June 25, 2020

The U.S. Food and Drug Administration has approved pembrolizumab for cutaneous squamous cell carcinoma whose disease has shown to not be curable by radiation or surgery.